Saturday, September 19, 2009

After years of research, drug for female sexual dysfunction' remains elusive

PHILADELPHIA _ The pharmaceutical industry's push to find a female version of Viagra has been full of letdowns.

Despite a decade of testing pills, patches, gels, nasal sprays and vaginal rings, there is still no approved drug for "female sexual dysfunction." More than a dozen drugs that reached late-stage testing have been abandoned, shelved or recycled for unrelated problems.

Market analysts still see multibillion-dollar opportunity in female sexual complaints. And two drugs _ LibiGel and Flibanserin _ doggedly aspire to become the first to win the FDA's imprimatur.

But female sex disorders have turned out to be far more difficult to define and quantify, let alone fix, than erectile dysfunction.

Kathy Kelley, the Texas founder of HysterSisters, a Web site for women who have had hysterectomies, testified before the U.S. Food and Drug Administration about the clear-cut need for drug therapies.

But she also understands how complex and individual those needs are.

"The brain is a woman's primary sex organ," she said in an interview.

With the 1998 approval of the first male impotence drug, entrepreneurs, researchers and many members of the fairer sex began lusting after a "pink" version.

Indeed, the first drugs to be tested in women were blood-vessel dilating agents that included Viagra and Cialis. The hope was that women would follow the classic male model of sexual response _ interest, arousal, orgasm.

They did not. Pfizer Inc.'s research showed that genital blood flow increased in Viagra-treated women as they watched erotic videos, but the arousal did not make them desire sex.

The complexity of female response has kindled intense debate. How to distinguish normal from abnormal, physiological from psychological, discontent from debilitation?

The answers have financial implications, especially as most drugs for women have been designed to be used regularly and indefinitely, not just as needed to prime the pump.

"In order to get insurance coverage, you have to prove this is a defined medical disorder that is really disrupting your life," said Leslie Sandberg, a market analyst at Trinity Partners in Waltham, Mass. "The vast majority of Viagra sales are cash pay; infrequently is it covered."

In 2000, the FDA issued preliminary guidelines to help companies plan human studies of drugs for female sexual complaints. The guidelines _ still not finalized _ reflected the consensus that had emerged among sex experts at industry-supported conferences around that time.

The FDA said that although "the definition of FSD continues to evolve," it "currently" has four "components:" decreased desire, decreased arousal, sexual pain and orgasm difficulties.

A woman with any one of these is dysfunctional _ but only if she feels "personal distress" about it. Sex experts had added distress to diagnostic criteria for female sexual dysfunction in 1998, publishing a report in the Journal of Urology and the Journal of Sex and Marital Therapy.

The addition was a recognition that some women are happy with sexual inactivity, but it also foreshadowed the challenge of treating a largely subjective disorder.

Diminished libido, now called hypoactive sexual desire disorder, is what most drugs have focused on. Effectiveness is judged by how many "satisfactory sexual events" the woman reports during the study period, typically three to six months. Unlike an erection, a satisfactory event is whatever the woman thinks it is, from cuddling to coitus.

In study after study, placebos increased satisfying events almost or just as much as the actual drug.

Poor performance was an issue with Intrinsa, the Procter & Gamble testosterone patch for women who experience "surgical menopause" after having their ovaries removed. In 2004, FDA advisers judged the product marginally effective, but rejected it because of a lack of safety data on long-term testosterone use.

P&G, which withdrew Intrinsa's U.S. application, won approval in numerous European countries. The product made just $2.5 million there last year, according to the information firm IMS Health. At that rate, P&G is a long way from recouping its costs; taking a new prescription drug to market costs hundreds of millions of dollars.

"I think the FDA put a pretty big wet blanket" on female sexual-dysfunction drug development, said Andrew Goldstein, a Washington obstetrician-gynecologist and president elect of the International Society for the Study of Women's Sexual Health, founded in 2001.

Another contentious challenge for the industry has been quantifying _ critics would say exaggerating _ how many women suffer from sexual disorders.

The most widely cited prevalence estimate is taken from a national survey published in 1999 in the influential Journal of the American Medical Association. The study found that 43 percent of American women ages 18 to 59 were sexually dysfunctional, compared with only 31 percent of men.

The really surprising thing, though, was that the rate wasn't higher. Here's what the survey, which did not inquire about personal distress, asked:

Over the past year, has there ever been a period of several months or more when you "lacked interest" in sex, or "didn't find pleasure" in it, or climaxed too quickly, or not at all, or found intercourse painful?

The results of the study _ funded by the federal government and the Ford Foundation _ became a staple of drug companies' efforts to raise awareness of the apparent epidemic of female sex disorders and the lack of drug remedies.

More recent surveys that included questions about distress found that 3 percent to 12 percent of women were sexually dysfunctional.

Yet the startling 43 percent statistic lives on.

Female Sexual Dysfunction Online, an educational Web site for doctors and researchers, offers several recent instructional presentations that cite that statistic. The Web site is supported by Intrinsa-maker Procter & Gamble and by Boehringer Ingelheim, which is developing Flibanserin.

The other company in the race for FDA approval is BioSante Pharmaceuticals. Last month, a news release about its testosterone gel, LibiGel, declared that "approximately 40 million American women suffer from some type of sexual disorder." Doing the math, that's 43 percent.

Lenore Tiefer, a psychologist and sex therapist at New York University, denounces this as "inflated epidemiology" calculated to make sexually healthy women worry that they're not.

For the past decade, she has led a widely reported campaign against what she calls "disease-mongering" by the drug industry and "agents of medicalization," such as publicists and gullible journalists. She promotes an alternative view of women's sexuality that stresses psychological, cultural and relationship factors.

"I'm frustrated by how little of our positive understanding of sexuality has gotten out," she said.

Goldstein's rebuttal: "I think these people aren't talking to women who have the problem. Baby boomers came of age during the 'sexual revolution' and took ownership of their sexuality. ... When they lose that, for some it's like losing a body part."

Goldstein is a consultant to Boehringer, the German company developing Flibanserin, a drug that acts on brain chemicals involved in mood. It was originally tested as an antidepressant until female subjects reported feeling no cheerier, just unexpectedly frisky.

(EDITORS: STORY CAN END HERE)

Boehringer won't say how Flibanserin has performed, but it hopes to complete studies of premenopausal women with low libido this year, spokeswoman Lara Crissey said.

BioSante, meanwhile, readily shares a study in which its daily testosterone gel increased surgically menopausal women's satisfying sexual events an average of five per month _ three more than a placebo.

Women make testosterone, the quintessential male hormone, in small amounts. It has always been a leading candidate for sexual therapy because for some women, it works. Prescription data show that several million of them order customized testosterone compounds from pharmacies or use men's testosterone therapies in lower doses.

However, prescriptions for all female hormones have plummeted in recent years because of a landmark federal study showing that the risks of estrogen-progestin therapy outweighed the benefits. Last month, Solvay Pharmaceuticals stopped making Estratest, a menopausal estrogen-testosterone product that had been prescribed for decades to boost female sex drive, even though it was not approved for that purpose.

The science and safety of female testosterone supplementation also remains unclear. In general, female libido declines with age, as does testosterone, yet blood levels of the hormone don't correlate with desire, arousal or function, studies show.

"Despite some 70 years of clinical use, we do not have a fully satisfactory rationale for testosterone therapy," Canadian gynecologist and sex researcher Rosemary Basson wrote last year in the Annals of Internal Medicine.

BioSante is undaunted. After lengthy negotiations with the FDA, the Lincolnshire, Ill., firm is conducting an unprecedented safety study of 3,000 women to track the incidence of breast cancer and cardiovascular events such as heart attacks. The company plans to seek approval after 12 months _ in late 2010 _ but will follow the women for an additional four years, chief executive Stephen Simes said.

"Competition has fallen away, and we're pushing ahead," Simes said. "Why? Our company is dedicated to women's health. I think women deserve options."

He also thinks LibiGel, at $4 a day, will feel the love: "I'm confident it will be between a $500 million- and a $1 billion-a-year product." generic viagra sildenafil Louisiana

Thursday, October 30, 2008

Unusual pants

A guy walked into a bar and sat down next to an extremely gorgeous woman. The first thing he noticed about her was her pants. They were skin-tight, high-waisted and had no zippers, buttons or velcro for opening them. After several minutes of puzzling over how she got the pants up over her hips, he finally worked up the nerve to ask her.

"Excuse me miss, but how do you get into your pants?" he asks.

"Well," she replied, "You can start by buying me a drink."

Drunk or Not?

OLE took off his shoes to avoid waking his wife, Lena. He tiptoed quietly toward the stairs leading to their upstairs bedroom, but misjudged the bottom step. As he caught himself by grabbing the banister, his body swung around and he landed heavily on his rump. A whiskey bottle in each back pocket broke and made the landing especially painful.

Managing not to yell, Ole sprung up, pulled down his pants, and looked in the hall mirror to see that his butt cheeks were cut and bleeding. He managed to quietly find a full box of Band-Aids and began putting a Band-Aid as best he could on each place he saw blood. He then hid the now almost empty box and shuffled and stumbled his way to bed. In the morning, Ole woke up with searing pain in his head and butt and Lena staring at him from across the room.

She said, "You were drunk again last night weren't you Ole?"

Ole said, "Why you say such a mean ting?"

"Well," Lena said, "it could be the open front door, it could be the broken glass at the bottom of the stairs, it could be the drops of blood trailing through the house, it could be your bloodshot eyes, but mostly...... it's all those Band-Aids stuck on the downstairs mirror."

Thursday, October 23, 2008

Cigarettes And Tampons

A man walks into a pharmacy and wanders up and down the aisles.
The sales girl notices him and asks him if she can help him.
He answers that he is looking for a box of tampons for his wife.
She directs him down the correct aisle.
A few minutes later, he deposits a huge bag of cotton balls and a ball of string on the counter. She says, confused, "Sir, I thought you were looking for some tampons for your wife?"
He answers, "You see, it's like this, yesterday, I sent my wife to the store to get me a carton of cigarettes, and she came back with a tin of tobacco and some rolling papers; cause it's sooo-ooo--oo-ooo much cheaper.
So, I figure if I have to roll my own .......... so does she.
(I figure this guy is the one on the milk carton!)

Wednesday, October 22, 2008

Little Johnny

Little Johnny's father had just returned home from a business trip, and he had a romantic evening planned with his wife. So, he sent his two older kids to the movies, but he couldn't persuade Little Johnny to go along.

Finally, he made a deal with Little Johnny, "If you go sit outside of the house, I'll give you five dollars for every man you see go by in a red hat."

An excited Little Johnny agreed.

Some time later, Little Johnny ran into the house and up to his parents bedroom. He banged on the door and shouted, "Hey, Dad, if you think your getting screwed in THERE, just wait until you come outside 'cause there's a Shriner convention going past our house."

Thursday, October 16, 2008

My lil' window lickin' son

My little boy has Lowe Syndrome, a rare genetic disorder which leaves him with physical disabilities and multiple and profound learning difficulties.
Last year his special needs school took him wheelchair ice skating for the first time. He really enjoyed the wind in his wee face, but they spent so long on the ice, that he was long overdue a nappy change, ( he is 10 and doubly incontinent ) He takes various kidney medications which leaves him with loose stools, which I am pretty immune to after a decade....
Anyway the shit had leaked out from the bottom of the nappy and travelled down his leg inside his trousers, into his socks and boots, special orthopaedic ones, all beautifully stitched.

Whoever changed his nappy, put the shoes in one bag and tried to rinse out the trousers, gave up and stuck them in another. All cool. It's not their job to launder shitty clothes.
Someone else came along to pack the school bags, saw the shoes and put them in with the wet shitty trousers to keep them together, not realising how disgusting the trousers were.

Three hours later the schoolbag arrives home, did you ever see pong lines in a cartoon when there's something smelly? I swear these were coming out of this bad when I opened it. The stench was unbelievable...wet shite, leather shoes, you do the maths.

I dealt with the trousers and socks, but the shoes were just plastered with shit, in all the stitching. To try and clean them I had to hand pick the shit out the stitching with a needle, with the tune running through my head " if my friends could see me now"
It only took 45 minutes.

Now that's what I call care in the community, what I earn my £43.15 per week for :(